Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Q3 2018 Earnings Presentation
10 slides from Puma Biotechnology's earnings presentation, Nov 1, 2018
Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update November 1, 2018 Copyright 2018 Puma Biotechnology
Slide 2: Forward-Looking Safe Harbor Statement
Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements, including statements regarding the timing of expected reimbursement and coverage decisions and regulatory approvals for NERLYNX. All statements other than historical facts are forward–looking statements and
Slide 3: Puma's Pharmacy and Distributor Network
Puma’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network Acaria Health Patients Accredo CVS Onco360 Diplomat Sites of Care Biologics Academic Hospitals Community Hospitals Specialty Distributor Network Physician Practices Other (VA, DoD) McKesson ASD / Oncology Supply Cardinal
Slide 4: Net Product Sales of $52.6 M in Q3-2018
Net Product Sales of $52.6 M in Q3-2018 NET SALES (IN $M) $60.0 $50.8 $52.6 $50.0 $40.0 $36.0 $30.0 $20.1 $20.0 $10.0 $6.1 $- Q3-2017 Q4-2017 Q1-2018 Q2-2018 Q3-2018 Copyright 2018 Puma Biotechnology 4
Slide 5: Active Patients on NERLYNX by Month
Active Patients on NERLYNX® by Month ESTIMATED TOTAL ACTIVE COMMERCIAL PATIENTS IN SP AND SD CHANNELS BY MONTH 2,500 2,139 1,987 2,000 1,887 1,812 1,738 1,680 1,499 1,500 1,379 Patients 1,199 985 1,000 775 646 500 451 263 105 5 - Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18
Slide 6: Time to First Dispense by Specialty Pharmacy
Time to First Dispense by Specialty Pharmacy PERCENT OF PATIENTS BY TIME TO FIRST DISPENSE 35.0% 33% 30.0% 25% 25.0% Percent of Patients 20.0% 16% 15.0% 10.0% 8% 8% 5.0% 4% 2% 2% 1% 1% 0.0% 5 or Less 6-10 11-15 16-20 21-30 31-45 46-60 61-90 91-120 121+ Days to First Dispense 74% of patients receive
Slide 7: 65% of Targeted Prescribers Reached
65% of Targeted Prescribers Reached CUMULATIVE PERCENT OF TARGET WRITERS REACHED 70% 65% 63% 60% 58% 51% 50% 40% 30% 25% 20% 10% 0% Q3-2017 Q4-2017 Q1-2018 Q2-2018 Q3-2018 * Call numbers reported for historical months may be slightly different from previous statements due to Veeva data updates Copyr
Slide 8: Europe and Canada Launch Progress
Europe and Canada Launch Progress Puma Europe and Canada Operations – Supply Chain and Commercial infrastructure work ongoing – Global Value Dossiers near completion – Reimbursement discussions with country health authorities – Expect launch in Germany 1H 2019 • Followed by France, United Kingdom an
Slide 9: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Expected Regulatory Approval Australia • 1H 2019 Israel • Mid 2019 China • 2H 2019 if priority review • 1H 2020 if standard review Latin America • 2H 2019 – Argentina South America • 2H 2019 – Chile • 2H 2019 – Ecuador • 1H 2020 – Mexico • 1H 202
Slide 10: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update November 1, 2018 Copyright 2018 Puma Biotechnology